- Previous Close
0.1350 - Open
0.1350 - Bid 0.1150 x --
- Ask 0.1500 x --
- Day's Range
0.1350 - 0.1350 - 52 Week Range
0.0600 - 0.2500 - Volume
3,000 - Avg. Volume
6,839 - Market Cap (intraday)
6.685M - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Apr 22, 2025 - Apr 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; MBEC Assay kit, a petri dish for biofilms, which are used for research and medical device testing of microbial biofilms; and AgreGuard, an antimicrobial for crop protection. It also provides antimicrobial contract research and antimicrobial testing; antimicrobial and anti-biofilm agents; antimicrobial and anti-biofilm materials; BEST assay testing; implanted medical devices; bacteriophage testing; and analytical services. The company serves customers in the areas of biofilm issues, including catheter and implant medical devices, antibiotic drug development, wound healing, paint and specialized coatings, water system antimicrobial agents, dental treatments and water line antimicrobial agents, and bacterial and fungal agricultural crop diseases, as well as disinfectants in food. Innovotech Inc. is headquartered in Edmonton, Canada.
innovotech.caRecent News: IOT.V
View MorePerformance Overview: IOT.V
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IOT.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IOT.V
View MoreValuation Measures
Market Cap
6.68M
Enterprise Value
6.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.49
Price/Book (mrq)
6.67
Enterprise Value/Revenue
4.30
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.01%
Return on Assets (ttm)
-22.56%
Return on Equity (ttm)
-26.14%
Revenue (ttm)
1.49M
Net Income Avi to Common (ttm)
-268.25k
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
377.14k
Total Debt/Equity (mrq)
9.34%
Levered Free Cash Flow (ttm)
-125.81k